NL6713016A - - Google Patents

Info

Publication number
NL6713016A
NL6713016A NL6713016A NL6713016A NL6713016A NL 6713016 A NL6713016 A NL 6713016A NL 6713016 A NL6713016 A NL 6713016A NL 6713016 A NL6713016 A NL 6713016A NL 6713016 A NL6713016 A NL 6713016A
Authority
NL
Netherlands
Application number
NL6713016A
Other versions
NL160805B (nl
NL160805C (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26253347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL6713016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NL6713016A publication Critical patent/NL6713016A/xx
Priority to NLAANVRAGE7811843,A priority Critical patent/NL173164C/xx
Publication of NL160805B publication Critical patent/NL160805B/xx
Application granted granted Critical
Publication of NL160805C publication Critical patent/NL160805C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL6713016.A 1966-09-23 1967-09-22 Werkwijze ter bereiding van een geneesmiddel met stimule- rende werking op beta-andrenergische receptoren onder toepassing van een hydroxyfenyl-aminoethanol-derivaat, waarvan de aminogroep slechts een substituent draagt. NL160805C (nl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7811843,A NL173164C (nl) 1966-09-23 1978-12-04 Werkwijze voor het bereiden van een hydroxyfenylaminoethanolderivaat met stimulerende werking op beta-adrenergische receptoren.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB18383/67A GB1200886A (en) 1966-09-23 1966-09-23 Phenylaminoethanol derivatives
GB1838367 1967-04-21

Publications (3)

Publication Number Publication Date
NL6713016A true NL6713016A (cg-RX-API-DMAC10.html) 1968-03-25
NL160805B NL160805B (nl) 1979-07-16
NL160805C NL160805C (nl) 1979-12-17

Family

ID=26253347

Family Applications (2)

Application Number Title Priority Date Filing Date
NL6713016.A NL160805C (nl) 1966-09-23 1967-09-22 Werkwijze ter bereiding van een geneesmiddel met stimule- rende werking op beta-andrenergische receptoren onder toepassing van een hydroxyfenyl-aminoethanol-derivaat, waarvan de aminogroep slechts een substituent draagt.
NL7809942A NL7809942A (nl) 1966-09-23 1978-10-02 Werkwijze voor het bereiden van een geneesmiddel met blokkerende werking op beta-adrenergische receptoren onder toepassing van een fenylaminoethanolderivaat.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL7809942A NL7809942A (nl) 1966-09-23 1978-10-02 Werkwijze voor het bereiden van een geneesmiddel met blokkerende werking op beta-adrenergische receptoren onder toepassing van een fenylaminoethanolderivaat.

Country Status (15)

Country Link
US (3) US3644353A (cg-RX-API-DMAC10.html)
AT (1) AT280996B (cg-RX-API-DMAC10.html)
BE (1) BE704037A (cg-RX-API-DMAC10.html)
CH (1) CH492676A (cg-RX-API-DMAC10.html)
CS (1) CS167874B2 (cg-RX-API-DMAC10.html)
CY (1) CY713A (cg-RX-API-DMAC10.html)
DE (1) DE1643224C3 (cg-RX-API-DMAC10.html)
DK (1) DK133618B (cg-RX-API-DMAC10.html)
FR (2) FR1557677A (cg-RX-API-DMAC10.html)
GB (1) GB1200886A (cg-RX-API-DMAC10.html)
IL (1) IL28643A (cg-RX-API-DMAC10.html)
NL (2) NL160805C (cg-RX-API-DMAC10.html)
NO (1) NO126014B (cg-RX-API-DMAC10.html)
PL (1) PL70430B1 (cg-RX-API-DMAC10.html)
SE (1) SE354061B (cg-RX-API-DMAC10.html)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1957706C3 (de) * 1968-11-18 1978-06-29 Pfizer Corp., Colon (Panama) Kernsubstituierte 3-Phenoxy-l-phenoxyalkylamino-propan-2-ole und Arzneimittel auf deren Basis
US4101579A (en) * 1969-02-06 1978-07-18 Allen & Hanburys Limited Phenethanolamine ethers
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
GB1266058A (cg-RX-API-DMAC10.html) * 1969-07-08 1972-03-08
GB1298494A (en) * 1970-06-17 1972-12-06 Allen & Hanburys Ltd Phenylethanolamine derivatives
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
BE794414A (fr) * 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
US4018825A (en) * 1972-07-27 1977-04-19 Warner-Lambert Company 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols
US4024255A (en) * 1973-04-05 1977-05-17 Allen & Hanburys Limited Tetrazole containing naphthyridine-3-carboxamides
GB1468673A (en) * 1973-05-07 1977-03-30 Allen & Hanburys Ltd Substituted benzamides
US4000192A (en) * 1973-05-07 1976-12-28 Allen & Hanburys Limited Pharmacologically active compounds
US3883560A (en) * 1973-07-05 1975-05-13 Colgate Palmolive Co Salicylamidophenethanolamines
US4046913A (en) * 1973-08-18 1977-09-06 Boehringer Ingelheim Gmbh 1-(M-alkanoyloxy-phenyl)-1-hydroxy-2-(N-lower alkyl-amino)-ethanes and salts thereof
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4093628A (en) * 1974-04-18 1978-06-06 American Home Products Corporation Thiophene ethanolamines
US4012528A (en) * 1974-06-03 1977-03-15 Smithkline Corporation α-AMINOALKYL-3-(1,2-DIHYDROXYETHYL)-4-HYDROXY-BENZYL ALCOHOLS HAVING β-ADRENERGIC STIMULANT ACTIVITY
US4173583A (en) * 1975-04-17 1979-11-06 Schering Corporation Diastereoisomers of 5-(1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
US4160036A (en) * 1975-07-29 1979-07-03 Allen & Hanburys Limited 4-Hydroxy-1,3-benzenedimethanol derivatives
GB1529972A (en) * 1975-07-29 1978-10-25 Allen & Hanburys Ltd Basic alcohols
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
JPS52113934A (en) * 1976-03-19 1977-09-24 Eisai Co Ltd Phenethylamine derivatives and bronchodilator containing the same
US4055658A (en) * 1976-05-17 1977-10-25 Mead Johnson & Company Cyanomethylphenethanolamines
US4127674A (en) * 1977-03-21 1978-11-28 Allergan Pharmaceuticals, Inc. Method of treatment for glaucoma
US4163053A (en) * 1977-12-27 1979-07-31 Schering Corporation Anti-hypertensive 5-[2-(substituted anilinoalkylamino)-1-hydroxyalkyl]salicylamides
IL57672A (en) * 1978-07-03 1983-03-31 Lilly Co Eli Phenethanolamines,their preparation and pharmaceutical compositions containing the same
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
DE2935062A1 (de) * 1978-09-06 1980-03-20 Degussa Substituierte aminoalkylguanidine, deren herstellung und arzneimittel
US4950783A (en) * 1978-09-20 1990-08-21 Schering Corporation Treatment of hypertension
US4590210A (en) * 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
US4275074A (en) * 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
IT1148741B (it) * 1980-11-28 1986-12-03 Zambeletti Spa L Procedimento per la preparazione dell'1-(3,5-dimetossi-4-idrossifenil)-2-(n-metilammino)etanolo cloridrato
US4486446A (en) * 1980-12-23 1984-12-04 Merck & Co., Inc. Aralkylaminoethanol heterocyclic compounds
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
CH656308A5 (fr) * 1982-05-27 1986-06-30 Glaxo Group Ltd Compositions pharmaceutiques contenant du salbutamol.
US4594359B1 (en) * 1982-05-27 1994-07-26 Glaxo Group Ltd Pharmaceutical compositions
GB2120942B (en) * 1982-05-27 1985-10-30 Glaxo Group Ltd Salbutamol compositions
CA1258454A (en) * 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
EP0103830A3 (de) * 1982-09-22 1985-07-31 Bayer Ag Wachstumsfördernde Phenylethylamin-Derivate
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4751071A (en) * 1983-12-01 1988-06-14 Alza Corporation Composition comprising salbutamol
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
IL74940A (en) * 1984-04-17 1988-06-30 Glaxo Group Ltd Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them
JPS6183147A (ja) * 1984-09-28 1986-04-26 Nippon Chemiphar Co Ltd 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤
US5250546A (en) * 1984-09-28 1993-10-05 Nippon Chemiphar Co., Ltd. Amino-alcohol derivatives and processes for their preparation
US4952729A (en) * 1986-09-05 1990-08-28 Schering-Plough Corp. Intermediates in the preparation of alpha1(((1,1-dimethylethyl) amino) methyl)-4-hydroxy-1,3-benzenedimethanol
EP0259159A3 (en) * 1986-09-05 1989-08-09 Schering Corporation Method for the preparation of alpha1- [[(1,1-Dimethylethyl) amino] methyl]-4-hydroxy-1,3-benzenedimethanol, and intermediates used in its preparation
US5011993A (en) * 1986-09-05 1991-04-30 Schering Corporation Method for the preparation of α1 [[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol
US5453418A (en) * 1988-03-07 1995-09-26 Eli Lilly And Company Ractopamine and growth hormone combinations
US5030640A (en) * 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
UA26230A (uk) 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US5011845A (en) * 1990-06-13 1991-04-30 Schering Corporation Cyclic diesters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
AU8184091A (en) * 1990-06-13 1992-01-07 Schering Corporation Esters and cyclic diesters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
US5118683A (en) * 1990-06-13 1992-06-02 Schering Corporation Esters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
IL119476A (en) * 1990-09-11 1999-10-28 Schering Corp Process for preparing acetals and hemi-acetals
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
YU59192A (sh) 1991-06-10 1994-12-28 Schering Corporation Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
EP1086688B1 (en) 1991-12-18 2004-03-03 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
CA2217950C (en) * 1995-04-14 2001-12-25 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
EP1547636A1 (en) 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
ZA994264B (en) * 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) * 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
GB0030171D0 (en) 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US7217724B2 (en) * 2002-06-12 2007-05-15 Dainippon Sumitomo Pharma Co., Ltd. Indole, indazole, and benzazole derivative
DE10249576B3 (de) * 2002-10-24 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (R)-Salbutamol
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
CA2507572C (en) 2002-12-10 2011-04-19 Sepracor Inc. Levalbuterol salt
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1577292A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
DE102005052127A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
CN100398512C (zh) * 2006-04-21 2008-07-02 华南农业大学 （±）α-[（取代胺基）甲基]-苯环取代基-苯甲醇类化合物的制备方法
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
JP5399902B2 (ja) 2006-08-22 2014-01-29 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
JP5825757B2 (ja) * 2007-02-11 2015-12-02 マップ・ファーマシューティカルズ・インコーポレイテッド 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするｄｈｅの治療上の投与方法
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
ES2615389T3 (es) 2007-10-05 2017-06-06 Acucela, Inc. Alcoxifenilpropilaminas para el tratamiento de la degeneración macular relacionada con la edad
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
CN101575298B (zh) * 2008-12-31 2013-03-06 上海予利化学科技有限公司 一种制备手性医药中间体2-氨基-1-苯乙醇的方法
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
JP5860398B2 (ja) * 2009-07-02 2016-02-16 アキュセラ インコーポレイテッド 視覚サイクルモジュレーターの薬理
JP2013537533A (ja) 2010-07-30 2013-10-03 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN102584609B (zh) * 2011-01-06 2015-05-27 上海医药工业研究院 一种沙美特罗的制备方法
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
HK1210969A1 (en) 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN102924382B (zh) * 2012-10-10 2014-11-19 淮海工学院 双水杨醛功能化的咪唑型双子离子液体及其制备方法
CN103086916B (zh) * 2012-10-10 2015-06-24 淮海工学院 席夫碱功能化的双子离子液体
MY176727A (en) 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators
EP3042892A1 (en) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisation of levosalbutamol tartrate
CN108947831A (zh) * 2018-07-13 2018-12-07 重庆康刻尔制药有限公司 一种沙丁胺醇中间体ⅲ的纯化方法
CN108623486A (zh) * 2018-07-13 2018-10-09 重庆康刻尔制药有限公司 一种沙丁胺醇中间体ⅴ盐酸盐的制备方法
CN112479908B (zh) * 2020-11-26 2025-05-27 江西天戌药业有限公司 一种硫酸沙丁胺醇杂质d的制备方法
CN112920064A (zh) * 2021-05-11 2021-06-08 仁合诚益医药技术(天津)有限公司 一种沙丁胺醇杂质化合物及其制备方法、检测方法和用途
PT4175619T (pt) 2021-07-09 2024-06-06 AstraZeneca Pharmaceuticals LP Composições, métodos e sistemas para administração de fármacos em aerossol
CN114159385A (zh) * 2021-09-27 2022-03-11 北京四环科宝制药股份有限公司 含有硫酸沙丁胺醇的药物组合物及其制备方法
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
GB202304652D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof
CN116283619A (zh) * 2023-03-30 2023-06-23 河北广祥制药有限公司 一种硫酸沙丁胺醇杂质及其制备方法

Also Published As

Publication number Publication date
DK133618C (cg-RX-API-DMAC10.html) 1976-11-08
NL160805B (nl) 1979-07-16
IL28643A (en) 1971-12-29
DE1643224A1 (de) 1972-03-02
US3642896A (en) 1972-02-15
NL160805C (nl) 1979-12-17
DE1643224C3 (de) 1979-08-09
FR1557677A (cg-RX-API-DMAC10.html) 1969-02-21
CY713A (en) 1973-11-26
DK133618B (da) 1976-06-21
AT280996B (de) 1970-05-11
BE704037A (cg-RX-API-DMAC10.html) 1968-02-01
CS167874B2 (cg-RX-API-DMAC10.html) 1976-05-28
NL7809942A (nl) 1979-01-31
US3705233A (en) 1972-12-05
FR8010M (cg-RX-API-DMAC10.html) 1970-07-27
GB1200886A (en) 1970-08-05
PL70430B1 (en) 1974-02-28
NO126014B (cg-RX-API-DMAC10.html) 1972-12-11
CH492676A (de) 1970-06-30
DE1643224B2 (de) 1978-11-23
SE354061B (cg-RX-API-DMAC10.html) 1973-02-26
US3644353A (en) 1972-02-22

Similar Documents

Publication Publication Date Title
FR8010M (cg-RX-API-DMAC10.html)
AT281852B (cg-RX-API-DMAC10.html)
AU5917865A (cg-RX-API-DMAC10.html)
AU428063B2 (cg-RX-API-DMAC10.html)
AU424443B2 (cg-RX-API-DMAC10.html)
AU433222B2 (cg-RX-API-DMAC10.html)
AU415165B1 (cg-RX-API-DMAC10.html)
AU421822B2 (cg-RX-API-DMAC10.html)
AU417216B2 (cg-RX-API-DMAC10.html)
AU414526B2 (cg-RX-API-DMAC10.html)
AU6703465A (cg-RX-API-DMAC10.html)
AU1111066A (cg-RX-API-DMAC10.html)
AU612166A (cg-RX-API-DMAC10.html)
AU1144366A (cg-RX-API-DMAC10.html)
AU218666A (cg-RX-API-DMAC10.html)
BE529218A (cg-RX-API-DMAC10.html)
BE624223A (cg-RX-API-DMAC10.html)
AU2390066A (cg-RX-API-DMAC10.html)
AU407778B2 (cg-RX-API-DMAC10.html)
AU411645B2 (cg-RX-API-DMAC10.html)
AU414093B2 (cg-RX-API-DMAC10.html)
AU6852465A (cg-RX-API-DMAC10.html)
AU855865A (cg-RX-API-DMAC10.html)
AU92366A (cg-RX-API-DMAC10.html)
BE284991A (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
NL80 Abbreviated name of patent owner mentioned of already nullified patent

Owner name: ALLEN HANBURY

V4 Lapsed because of reaching the maximum lifetime of a patent